October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
|Articles|October 29, 2021
Daily Medication Pearl: Atogepant (Qulipta) for Episodic Migraine
Author(s)Saro Arakelians, PharmD
Atogepant is indicated for the preventive treatment of episodic migraine in adults.
Advertisement
Medication Pearl of the Day: Atogepant (Qulipta)
Indication: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.
Insight:
- Dosing: The recommended dosage is 10 mg, 30 mg, or 60 mg taken orally once daily with or without food. Severe renal impairment or end-stage renal disease take 10 mg once daily.
- Dosage form: Tablets 10 mg, 30 mg, and 60 mg
- Adverse events (AEs): The most common AEs (at least 4% and greater than placebo) are nausea, constipation, and fatigue.
- Mechanism of action: Atogepant is a CGRP receptor antagonist.
- Manufacturer: AbbVie
Sources:
Advertisement
Related to this article
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Advertisement
Advertisement
Trending on Pharmacy Times
1
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
2
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
3
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5